Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy

Circulation

Volumn 102, Issue 5, 2000, Pages 591-596

  Rockson, Stanley G ^a   Lorenz, David P ^a   Cheong, Wai Fung ^b   Woodburn, Kathryn W ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHARMACYCLICS INC   (United States)

Author keywords

Atherosclerosis; Photoangioplasty; Photodynamic therapy; Restenosis

Indexed keywords

AMINOLEVULINIC ACID; BENZOPORPHYRIN DERIVATIVE; HEMATOPORPHYRIN DERIVATIVE; LUTETIUM TEXAPHYRIN; MOTEXAFINE LUTETIUM; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; PURPURIN; UNCLASSIFIED DRUG;

ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0034255378     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.5.591     Document Type: Article

References (56)

1. How does photodynamic therapy work?
2. Photosensitizers: Therapy and detection of malignant tumors
3. Photodynamic therapy
4. Photodynamic therapy of atherosclerosis and restenosis: A potentially exciting new treatment method
5. The role of subcellular localization in initiation of apoptosis by photodynamic therapy
6. Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: Role of activated neutrophils
7. The effect of photodynamic therapy on the microcirculation
8. Photodynamic therapy of normal and balloon-injured rat carotid arteries using 5-amino-levulinic acid
9. In vitro uptake of dicarboxylic porphyrins by human atheroma: Kinetic and analytical studies
10. Porphyrin retention and photodynamic treatment of diet induced athemsclerotic lesions in pigs
11. Preferential uptake of a water soluble phthalocyanin by atherosclerotic plaques in rabbits
12. In vivo photosensitizer enhanced laser angioplasty in atherosclerotic Yucatan miniswine
13. In vitro and in vivo uptake of benzoporphyrin derivative into human and miniswine atherosclemtic plaque
14. Light sources for photodynamic therapy
15. Photophysics and instramentation for poyphyrin detection and activation
16. On the evolution of some endoscopic light delivery systems for photodynamic therapy
17. Photosensitization
18. In-vivo canine coronary artery laser irradiation: Photodynamic therapy using dihematoporphyrin ether and 632 nm laser
19. Induction or prevention of intimal hyperplasia by photodynamic therapy in the porcine model
20. Lutetium texaphyrin (PCI-0123): A near-infrared, water-soluble photosensitizer
21. Phototherapy of cancer and atheromatous plaque with texaphyrins
22. Photodynamic therapy of normal rat arteries after photosensitisation using disulphonated aluminum phthalocyanine and 5-aminolaevulinic acid
23. Fluorescence of experimental atheromatous plaques with hematoporphyrin derivative
24. Hematoporphyrin uptake in atherosclerotic plaques: Therapeutic potentials
25. Photosensitization of experimental atheromas by porphyrins
26. Comparative study of the selective uptake of hematoporphyrin derivative components into experimental atheromatous plaques: Potential for laser angioplasty
27. Effects of hematoporphyrin derivative and photodynamic therapy on atherosclerotic rabbits
28. Haematoporphyrin and atherosclerosis in the broad-breasted white turkey: Distribution and quantitation in thoracic and abdominal aorta
29. Porphyrin accumulation by atheromatous plaques of the aorta
30. Responses of cultured smooth muscle cells from human nonatherosclerotic arteries and primary stenosing lesions after photoradiation: Implication for photodynamic therapy of vascular stenosis
31. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): Mechanisms and clinical results
32. Hemodynamic effects of 5-aminolevulinic acid in humans
33. Chloroaluminum sulfonated phthalocyanine partitioning in normal and intimal hyperplastic artery in the rat: Implications for photodynamic therapy
34. Transadventitial localization of atheromatous plaques by fluorescence emission spectrum analysis of mono-L-aspartyl chlorin e6
35. 2 for the treatment of vascular disease: Dose/response study in NZW rabbits
36. Presence of blood significantly decreases transmission of 630 nm laser light
37. Selective uptake of texaphyrins by atheromatous plaque
38. Texaphyrins: Synthesis and applications
39. Frequency and consequences of intimal hyperplasia in specimens retrieved by directional atherectomy of native primary coronary artery stenoses and subsequent restenosis
40. Photoeradication and imaging of atheromatous plaque with texaphyrins
41. Incidence of restenosis after successful coronary angioplasty: Time-related phenomenon: A quantitative angiographic study in 342 consecutive patients at 1, 2,3, and 4 months
42. Relation between activated smooth muscle cells in coronary-artery lesions and restenosis after atherectomy
43. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty
44. Accumulation of macrophages in the arterial vessel wall following experimental balloon angioplasty
45. Photodynamic therapy inactivates extracellular matrix-basic fibroblast growth factor: Insights to its effect on the vascular wall
46. Photodynamic therapy inhibits transforming growth factor beta
47. Differential effect of Photofrin II on growth of human smooth muscle cells from non atherosclerotic arteries and atheromatous plaques in vitro
48. Differential modulation of vascular endothelial and smooth muscle cell function by photodynamic therapy of extracellular matrix: Novel insights into radical-mediated prevention of intimal hyperplasia
49. Application of photodynamic therapy to the treatment of atherosclerotic plaques
50. Photodynamic therapy of arteries: A novel approach for treatment of experimental intimal hyperplasia
51. Inhibition of intimal hyperplasia by photodynamic therapy using Photofrin
52. Local photodynamic therapy reduces tissue hyperplasia in an experimental restenosis model
53. Cytotoxic effect of photodynamic therapy with Photofrin II on intimal hyperplasia
54. Importance of the treatment field for the application of vascular photodynamic therapy to inhibit intimal hyperplasia
55. Photodynamic therapy trials with motexafin lutetium (Lu-Tex) in patients with locally recurrent breast cancer
56. Selective hematoporphyrin (HMD) application in arterial vessels using a porous balloon catheter results in equivalent levels as compared to high-dose systemic administration